{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:17Z","timestamp":1791358037033,"version":"4.3.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvoice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Voice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jvoice.2022.12.028","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T13:25:06Z","timestamp":1674048306000},"page":"890-895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab Treatment"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-5474","authenticated-orcid":false,"given":"Antonia","family":"Lagos-Villaseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-8777","authenticated-orcid":false,"given":"Maxime J.","family":"Kinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1571-1086","authenticated-orcid":false,"given":"Clark A.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvoice.2022.12.028_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103660","article-title":"Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"173","author":"Udayakumar","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0002","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12094-022-02815-w","article-title":"SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)","volume":"24","author":"Valderrama","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0003","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2217\/fon-2021-1633","article-title":"Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC","volume":"18","author":"Jin","year":"2022","journal-title":"Futur Oncol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12957-022-02549-7","article-title":"Clinical benefits of PD-1\/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105824","article-title":"Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers","volume":"127","author":"Patil","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2022.03.008","article-title":"Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: a systematic literature review","volume":"166","author":"Juarez-Garcia","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0007","first-page":"422","article-title":"Prescription patterns, recurrence, and toxicity rates of adjuvant treatment for stage III\/IV melanoma\u2014a real world single-center analysis","volume":"11","author":"Hoffmann","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0008","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0009","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.3747\/co.27.5111","article-title":"Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy","volume":"27","author":"Khan","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0010","series-title":"Immune Checkpoint Proteins: Signaling Mechanisms and Molecular Interactions in Cancer Immunotherapy","author":"Gaikwad","year":"2022"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the lite","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0012","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1078155220946370","article-title":"Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: a case report and review of literature","volume":"27","author":"Cosimati","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0014","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0015","first-page":"1","article-title":"Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report","volume":"14","author":"Chatterjee","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0016","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/CJI.0000000000000280","article-title":"A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: brief communication","volume":"42","author":"Bezinelli","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0018","article-title":"Laryngeal pemphigoid evolution and response to treatment","author":"Barmatz","year":"2021","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0019","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/jdv.16036","article-title":"Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms","volume":"34","author":"F\u00e4ssler","year":"2020","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0020","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.oooo.2021.05.012","article-title":"Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events","volume":"132","author":"Duan","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103036","article-title":"Mucous membrane pemphigoid","volume":"21","author":"Du","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jvoice.2017.03.025","article-title":"Epiglottitis as the presenting sign of mucous membranous pemphigoid: a case report","volume":"32","author":"Carmel-Neiderman","year":"2018","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0023","series-title":"Cummings Otolaryngology Head and Neck Surgery","author":"Flint","year":"2021"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01030","article-title":"Gliptin accountability in mucous membrane pemphigoid induction in 24 Out of 313 patients","volume":"9","author":"Gaudin","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0026","unstructured":"Pile HD, Yarrarapu SNS, Crane JS. Drug Induced Pemphigus. StatPearls. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29110080. Published July 10, 2022."},{"key":"10.1016\/j.jvoice.2022.12.028_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2015.06.033","article-title":"Skin biopsy: biopsy issues in specific diseases","volume":"74","author":"Elston","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0028","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/ced.14662","article-title":"Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab","volume":"46","author":"Baniel","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jvoice.2022.12.028_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Journal of Voice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199722004295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199722004295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:58:03Z","timestamp":1781312283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0892199722004295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0892199722004295"],"URL":"https:\/\/doi.org\/10.1016\/j.jvoice.2022.12.028","relation":{},"ISSN":["0892-1997"],"issn-type":[{"value":"0892-1997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Voice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvoice.2022.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Voice Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}